Regne Unit - anglès - MHRA (Medicines & Healthcare Products Regulatory Agency)

bristol laboratories ltd - naproxen - oral tablet - 250mg

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - beclometasone dipropionate 250ug;   - aerosol inhaler, metered dose - 250 mcg/dose - active: beclometasone dipropionate 250ug   excipient: ethanol norflurane

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

roche products (nz) ltd - mycophenolate mofetil 250mg;   - capsule - 250 mg - active: mycophenolate mofetil 250mg   excipient: croscarmellose sodium gelatin magnesium stearate povidone pregelatinised maize starch - cellcept is indicated for the prophylaxis of solid organ rejection in adults receiving allogeneic organ transplants. cellcept is indicated for the prophylaxis of organ rejection in paediatric patients (2 to 18 years) receiving allogeneic renal transplants.

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

leo pharma limited - sodium fusidate 250mg; sodium fusidate 250mg - film coated tablet - 250 mg - active: sodium fusidate 250mg excipient: colloidal silicon dioxide crospovidone gelatin hypromellose lactose monohydrate magnesium stearate microcrystalline cellulose povidone purified talc titanium dioxide active: sodium fusidate 250mg excipient: colloidal silicon dioxide crospovidone dl-alpha tocopheryl acetate hypromellose lactose monohydrate magnesium stearate microcrystalline cellulose purified talc titanium dioxide - treatment of localised as well as generalised staphylococcal infections (e.g. abscesses, furunculosis, wound infections, pneumonia, peritonitis, osteomyelitis, septicaemia, enteritis and otorhinolaryngeal infections).

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

rex medical ltd - levetiracetam 250mg - film coated tablet - 250 mg - active: levetiracetam 250mg excipient: colloidal silicon dioxide croscarmellose sodium magnesium stearate maize starch opadry blue 03b50643 povidone purified water   - everet tablets are indicated for: · use in epileptic patients aged 4 years and older, initially as add-on therapy, in the treatment of partial onset seizures with or without secondary generalisation. · monotherapy in the treatment of partial onset seizures, with or without secondary generalisation, in patients from 16 years of age with newly diagnosed epilepsy. · add-on therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with juvenile myoclonic epilepsy (jme). · add-on therapy in the treatment of primary generalised tonic-clonic seizures in adults and children from 4 years of age with idiopathic generalised epilepsy (ige).

Nova Zelanda - anglès - Medsafe (Medicines Safety Authority)

takeda new zealand limited - octocog alfa 250 [iu] - injection with diluent - 250 iu - active: octocog alfa 250 [iu] excipient: albumin calcium chloride dihydrate histidine hydrochloric acid macrogol 3350 sodium chloride water for injection - in haemophilia a (classical haemophilia) for the prevention and control of haemorrhagic episodes. · in the perioperative management of patients with haemophilia a (classical haemophilia).

Singapur - anglès - HSA (Health Sciences Authority)

pfizer private limited - moroctocog alfa (af-cc) - injection, powder, for solution - 250iu/vial - moroctocog alfa (af-cc) 250iu/vial

Singapur - anglès - HSA (Health Sciences Authority)

grifols asia pacific pte. ltd. - antitetanus immunoglobulin (human) - injection - 250 iu/ml - antitetanus immunoglobulin (human) 250 iu/ml

Singapur - anglès - HSA (Health Sciences Authority)

grifols asia pacific pte. ltd. - antihemophilic factor viii (human) - injection, powder, for solution - 250 iu/vial - antihemophilic factor viii (human) 250 iu/vial

Singapur - anglès - HSA (Health Sciences Authority)

pfizer private limited - sultamicillin - powder, for suspension - 250 mg/5 ml - sultamicillin 250 mg/5 ml